Freely Filtered, a NephJC Podcast

Freely Filtered 055: STOP ACE!

Jan 29, 2023

01:18:12

Creator website

Highlights

AI Chapters

Episode notes

Is Dynamic Prediction More Useful Than Static Prediction?

02:12

Randomized Randomization of Chronic Kidney Disease

02:43

I'm Going to Finish My Thought

02:25

Introduction

2min

Is ACE ARB a Drug?

2min

Stop ACE Inhibition in Advanced Chronic Kidney Disease

3min

ACE Inhibitors and ARBs in CKD Patients?

2min

Advanced CKD

2min

Is Diabetic Nephropathy a Good Selection Criteria?

2min

ACE Inhibition in Heart Failure

2min

Spire in the Lactone, Is Hard?

2min

What's the Difference in GFR?

3min

10.

Is There Any Thought About Blinding Endpoint Adjudication?

2min

11.

I'm Not a Trialist, but It's an Expensive Trial

2min

12.

The Amad Study

2min

13.

Is It a Cohort Study?

2min

14.

ACE Inhibitor ARBs - I'm Going to Jump in Because Soft Knoll Jumped In

2min

15.

The Conword Is the Zila. I'm Not a Conword. I Have Strong Opinions

2min

16.

ACE Inhibitors and ARBs

2min

17.

Randomized Randomization of Chronic Kidney Disease

3min

18.

ACEIL and Diabetic Nephropathy in the UK

2min

19.

Is the ASK Trial a Good Idea?

2min

20.

The Ask Trial

2min

21.

Is There a Selection Bias in CPD?

2min

22.

ACE Inhibitors

2min

23.

The Primary Outcome, No Difference

2min

24.

Dialysis and GFR Loss - Is That a Better Choice?

2min

25.

Is Dynamic Prediction More Useful Than Static Prediction?

2min

26.

Is RAS Inhibition a Risk to Blood Pressure Control?

2min

27.

Hyperkalemia in Type Two Diabetes?

2min

28.

Observational Study on Proteinuria

2min

29.

Observational Studies in Advanced CKD

2min

30.

ACE Inhibitors and ARBs in CKD Patients?

2min

31.

I'm Going to Finish My Thought

2min

32.

How to Emulate a Clinical Trial?

3min

33.

Would You Trust the Observational Study?

3min

34.

The Last Nerdy Question

2min

35.

Emulator Trial Design

2min

36.

Doxazusin Is Better Than Spire on the Lactone

2min

37.

Stop ACE Inhibition

2min

38.

Do You Have a Tubular Secretion?

2min

39.

A Tubular Secretion for You, Laura

2min

The Filtrate:

Joel Topf

Swapnil Hiremath

Jordy Cohen

With Special Guest:

Laurie Tomlinson. @Roxytonin Nephrologist at University Hospitals Sussex and research hero of Jordy.

Editor:

Priya Yenebere

Show Notes:

STOP-ACE in pubmed: Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease

STOP-ACE Summary in NephJC

Prior data showing preservation of renal function by stopping ACEi: The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease

Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency: NEJM

Dr. Tomlinson’s article on creatinine changes in RASi from 2017: Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study NephJC | PubMed

Accuracy of eGFR at low GFR: A new equation to estimate glomerular filtration rate

Strong opinions, loosely held.

“Permissive AKI” with treatment of heart failure. Editorial by Chirag Parish and Steven Coca

The rational for NICE avoiding RASi in black patients: Hypertension and ethnic group

AASK trial showing superiority of RASi in African Americans. JAMA

ALLHAT post-hoc analysis of outcomes by self-reported race. JAMA | PubMed

Sophisticated Swedish observational study that Swap loved. Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes: A Nationwide Study

Target Trials in Nephrology Dr Edouard Fu grand rounds at Ottawa Nephrology, YouTube

Target Trial EmulationA Framework for Causal Inference From Observational Data by Miguel Hernán in JAMA

Tubular Secretions

Jordy: Third season of His Dark Materials on HBO

Swap: Movies by Wes Anderson on Disney Plus

Laurie: The Book, “Nearly All the Men in Lagos are Mad”

Jordy: How Medicine Works and When It Doesn't: Learning Who to Trust to Get and Stay Healthy | Amazon

Joel EO | NYT Review

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.